

# Increase Predictability of Clinical Trial Delivery

## What Makes a Catalyst Site?



Proven track record of meeting or exceeding performance goals




Sites are prequalified and managed by a site relationship manager



Agreed upon quality, contract and communication standards across the Catalyst Networks




Therapeutically aligned with our Business Units



## The Catalyst Site Network

was introduced in 2016 to strengthen collaborations with clinical research sites worldwide. The objective of the program is to increase predictability and, by harnessing input and insights from sites across the globe, drive continuous improvement and develop best practices and new methodologies in the delivery of clinical research.



## Proven Performance

**71%** higher enrollment rate in Oncology

**38%** higher enrollment rate in Ophthalmology

**23%** higher enrollment rate in Psychiatry



Voted the "Top CRO to work with" among top 10 global CROs by investigative sites in the Centerwatch 2017 Global Site Survey.

2017 and 2018 Society for Clinical Research Sites Eagle Award Winner

# Catalyst | Site

## Performance Metrics

Shortening the Distance from Lab to Life®



### Catalyst Oncology Network

#### Catalyst Oncology Analysis

Comparing Catalyst site performance versus non-Catalyst site performance demonstrates:

- Enrollment rates 71 percent higher at Catalyst sites
- Enroll 131 percent more patients than non-Catalyst sites
- Catalyst Oncology sites are 41 percent faster to progress from SIV to FPI



### Catalyst Vaccine Network

#### Catalyst Vaccine Analysis

Analysis of current vaccine case studies show:

- An average of 75 percent time reduction in PIQ cycle time when using the Catalyst mCDA
- 84 percent time reduction for CTA execution when sponsor utilized Catalyst mCTA versus a 36 percent time reduction when the sponsor did not use the mCTA
- Significantly exceeded enrollment expectations on both studies

*In summary, the Catalyst Vaccine network demonstrates fewer transaction cycles result in accelerated study start-up timelines.*



### Catalyst Psychiatry Network

#### Catalyst Psychiatry Analysis

Comparing Catalyst site performance versus non-Catalyst site performance demonstrates:

- Enrollment rates 23 percent higher at Catalyst sites
- Enroll 32 percent more patients than non-Catalyst sites
- Catalyst Psychiatry sites are 30 percent faster to progress from SIV to FPI



### Catalyst Ophthalmology Network

#### Catalyst Ophthalmology Analysis

Comparing Catalyst site performance versus non-Catalyst site performance demonstrates:

- Enrollment rates 38 percent higher at Catalyst sites
- Enroll 50 percent more patients than non-Catalyst sites
- Catalyst Ophthalmology sites are 37 percent faster to progress from SIV to FPI

### Psychiatry SAG

Our CNS Psychiatry Protocol Optimization Site Advocacy Group (SAG) is a collaboration between Syneos Health and the Society for Clinical Research Sites (SCRS). The SAG provides early feedback on synopses, protocols and draft study designs.

This provides vital feedback and information to our sponsors during critical phases of protocol development and helps to shape future clinical trials. The Catalyst Site Network and the SAG ensures our sponsors are able to mitigate against potential risks to the project while placing the right protocol at the right sites.

**Becoming part of the Syneos Health Catalyst Community is easy—to join please register at [connect.syneoshealth.com](https://connect.syneoshealth.com)**

### About Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Learn more about how we are **shortening the distance from lab to life®** at [syneoshealth.com](https://syneoshealth.com).

**Catalyst | Site**